GlassScriptPhysician profile
Jason A Higgins
NPI 1891887022
$7,378.12
in general payments reported to CMS, 2019-2025
21 companies · $2,030 in 2025
The $2,030 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,437 · 2020: $311 · 2021: $309 · 2022: $2,687 · 2023: $325 · 2024: $279 · 2025: $2,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,451 · Food and Beverage: $1,089 · Debt Forgiveness: $94.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,450.75 |
| Food and Beverage | $1,089.04 |
| Debt Forgiveness | $94.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,663.08 | 2019-2025 | Inspace, 1788 |
| Arthrex, INC. | $2,051.39 | 2019-2025 | |
| Alon Medical Technology | $1,106.38 | 2019-2025 | |
| Zimmer Biomet Holdings, INC. | $371.27 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $200.50 | 2019-2025 | Exparel, Iovera, Zilretta |
| Horizon Therapeutics Plc | $176.19 | 2019-2022 | |
| Pacira Therapeutics, INC. | $147.24 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $139.21 | 2019-2025 | Euflexxa |
| Zimvie INC. | $94.33 | 2023 | |
| Bioventus LLC | $59.96 | 2023-2025 | Durolane, Durolane |
| Vericel Corporation | $57.35 | 2020-2022 | |
| Abbvie INC. | $55.75 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $47.81 | 2019-2022 | |
| Depuy Synthes Sales INC. | $42.67 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $42.51 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.62 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $25.29 | 2021 | |
| Kerecis Limited | $22.41 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Advanced Oxygen Therapy INC. | $16.52 | 2024 | Topical Oxygen Chamber For Extremities |
| Fidia Pharma USA INC. | $12.01 | 2020 | |
| Pfizer INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Higgins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.